Background. A CD8 cutaneous lymphoinfiltrative disease has been described in human immunodeficiency virus (HIV)-infected patients presenting with a severe erythroderma. The true nature of this severe skin infiltrative disorder is still elusive. Although some clinical features of this syndrome have raised the hypothesis of its malignant nature in initial observations, several studies have provided stronger support to the hypothesis that it is a reactive pseudotumoral process.
Methods. From 1995 through 2008, 8 HIV type 1 (HIV-1)-infected patients presenting with a chronic skin eruption, diagnosed as CD8 T cell infiltration of the skin, were studied.
Results. All patients showed diffuse infiltrated skin with superficial lymphadenopathy. A profound CD4 + lymphocytopenia and eosinophilia were other major features. Histological and immunostaining analysis revealed a predominant dermal and epidermal infiltration by CD8 + T cells belonging to the cytotoxic lineage, without evidence for a monoclonal status by polymerase chain reaction-based molecular analysis of lesional skin. A remission of skin symptoms occurred in all cases following highly active antiretroviral therapy, which paralleled the decrease of HIV-1 RNA load and the increase of CD4 + peripheral blood absolute count. Conclusions. Altogether, these results emphasize the reactive, nonmalignant nature of this syndrome and strongly support the coupling between HIV-induced immune deficiency and uncontrolled CD8 activation.
The incidence of lymphoproliferative disorders is known to be higher among human immunodeficiency virus (HIV)-infected patients than among HIV-seronegative individuals [1] . Most of these lymphoproliferations consist of intermediate-or high-grade lymphomas belonging to the B lineage, whereas T cell lymphoproliferative disorders infrequently occur dur-ing the course of HIV infection. Only a few cases of cutaneous T cell lymphomas (CTCL), including mycosis fungoides and Sézary syndrome, have been reported [2] [3] [4] [5] [6] [7] [8] [9] [10] . A CD8 cutaneous lymphoinfiltrative disease exhibiting some features of CTCL has been described in HIV-infected patients presenting with a severe erythroderma [11] [12] [13] [14] [15] [16] [17] . This entity has been denominated as pseudo-Sézary syndrome [11] , CD8 cutaneous pseudolymphoma [18] , or pigmented erythroderma [14] , although some have adopted the more descriptive term atypical cutaneous lymphoproliferative disorder [16] .
The true nature of this severe skin infiltrative disorder is still elusive. Although some clinical features of this syndrome raised the hypothesis of its malignant nature in initial observations, several studies have pro- vided a stronger support to the hypothesis of a reactive, pseudotumoral process. Indeed, the consistent expression of CD8 by infiltrating lymphocytes without evidence for immunophenotypic aberration and its polyclonal or oligoclonal patterns in previous studies both favor its characterization as a pseudolymphoma entity, rather than its inclusion in the primary cutaneous lymphoma spectrum [11, 12, 14, 15] . Supporting this latter hypothesis, we previously demonstrated that CD8 + cytotoxic T lymphocytes infiltrating the skin of some of these patients specifically reacted against HIV antigens [13, 18] . This latter observation provided a rational basis for highly active antiretroviral therapy (HAART) as a first-line treatment in patients affected by this rare syndrome. However, prospective studies investigating the course of these skin symptoms during antiretroviral therapy have not been reported so far, and the remission of HIV-related CD8 + cutaneous pseudolymphoma following HAART has only been described in a single case [17] . In the present work, we report 8 cases of severe HIV-related CD8 T cell skin infiltrative disease following a favorable course of HAART, with evidence for a striking correlation between clinical remission and immune reconstitution and control of HIV replication.
PATIENTS AND METHODS

Study patients.
From 1995 through 2008, we observed 8 HIV type 1 (HIV-1)-infected patients presenting with a chronic skin eruption, diagnosed as CD8 T cell infiltration of the skin, according to clinicopathological features described elsewhere (ie, a generalized eruption following a chronic course and a predominant CD8 phenotype of the cutaneous lymphocytic infiltrate on immunohistochemical analysis, defined as CD8 + cells representing 160% of infiltrating lymphocytes [12, 14] ). Essential characteristics of study patients are summarized in Table  1 . All patients were male, with a mean age of 41.3 years (range, 32-56 years). Only 1 patient received antiretroviral therapy, with nevirapine, lamivudine, and zidovudine, before the onset of skin symptoms.
Histopathological and immunohistochemical studies. Eighteen skin and 2 lymph node formalin-fixed paraffin-embedded biopsies were available from 8 study patients. Twomicrometer-thick sections were obtained from paraffin-embedded tissue and were stained with hematoxylin and eosin. The slides were reviewed by 2 dermatopathologists (M.B. and J.R.). Immunohistochemical analysis on paraffin-embedded material was performed with primary antibodies against the following antigens: CD3 (polyclonal; dilution, 1:50; Dako), CD8 (clone 144B; dilution, 1:50; Dako), CD20 (clone L26; dilution, 1:400; Beckman Coulter), granzyme B (clone GrB7; dilution, 1:50; Dako), T cell-restricted intracellular antigen (clone 2G9A10F5; dilution, 1:500; Beckman Coulter), and CD45-RO (clone UCHL1; dilution, 1:50; Dako). Subsequent applications of biotinylated secondary antibodies and then of the avidin-biotinylated peroxidase complex were performed, followed by revelation with the DAB detection kit (Dako). Frozen skin biopsies were available for 8 patients. Frozen sections were fixed with acetone and were immunostained with a primary antibody against perforin (clone dG9; dilution, 1:1000; Beckton Dickinson). The percentage of mononuclear cells expressing different antigens was estimated independently by M.B. and J.R. Appropriate positive and negative control reactions were performed.
Molecular analysis of clonality. The clonality status was assessed using polymerase chain reaction multiplex amplifications of TCRg V(D)J junctions performed on DNA extracted from 9 skin biopsies for 6 patients and from 12 samples of peripheral blood mononuclear cells for 5 patients, as described elsewhere [19] .
Virologic and immunologic studies. Plasma HIV-1 RNA levels were measured by quantitative reverse-transcriptase polymerase chain reaction (Amplicor HIV Monitor Test; Roche Molecular Systems). The detection threshold was 1.3 log 10 copies/mL (ie, 20 copies/mL).
Lymphocyte populations were analyzed in fresh whole blood EDTA samples by direct 3-or 4-color immunofluorescence with a Facscalibur analyzer (Becton Dickinson). The percentages and absolute values of main lymphocyte subset T cells were determined using the following antibodies: CD45-PerCP, CD3-FITC, CD4-APC, CD8-PE or -PerCP, DR-PE, and CD38-PE (Becton Dickinson). Evaluation of response during treatment. The extent of cutaneous involvement was evaluated on the basis of the body surface area clinically involved with skin lesions. A complete response was defined as the resolution of all clinical skin lesions. Partial response was defined as reduction of at least 50% in the surface of lesions. Less than 50% regression of lesions, stability, or progression were considered to be lack of response to therapy.
RESULTS
Patients presented with an eruption lasting for a median duration of 13 months (range, 3-36 months) at the time of diagnosis. Cutaneous lesions consisted of erythematous, infiltrated plaques progressively extending to result in erythroderma in 7 case patients, whereas 1 patient presented with multiple plaques involving the face, the trunk, and the thighs. Pruritus, intense lichenification, scaling and fissuring, and hyperpigmented areas were consistent findings. Hyperkeratosis of palms and soles was observed in 3 patients. Worsening of skin symptoms after ultraviolet light exposure was evident in 6 case patients. A superficial, diffuse lymphadenopathy was consistently detected, whereas splenomegaly was present in 1 patient.
The Histopathological analysis of skin biopsies demonstrated a papillary and sometimes middermal infiltrate of mononuclear cells, consisting of a vast majority of small lymphocytes admixed with rare histiocytes, in all cases (Figure 1) . In 1 patient, the biopsies showed intermediate-sized lymphocytes with slight nuclear atypias. Otherwise, the lymphocytes were small sized without nuclear atypia. The density of the infiltrate displayed important interindividual and intraindividual variations from one biopsy to another. Dermatitis-like and mycosis fungoides (CTCL)-like patterns could sometimes be found in different biopsies performed in the same patient. Epidermal exocytosis of lymphocytes and melanophages of the superficial dermis, a marker of pigment incontinence, were a frequent feature. ) could be detected. The proportion of skin lymphocytes expressing granzyme B and T cell-restricted intracellular antigen ranged from !5% to 30% and 50%, respectively ( Figure 1 and Table 4 ).
Histological analysis of lymph nodes from 2 patients revealed that the normal nodal architecture was replaced by a dense infiltrate of small and medium-sized lymphocytes, with CD8 expression in 75%-100% of them. These lymphocytes were admixed with eosinophils ( Figure 2) .
Polymerase chain reaction analysis of Vg-Jg rearrangements in skin biopsies and peripheral blood mononuclear cell samples all revealed a polyclonal pattern. These results were confirmed by Southern blot analysis using a Cß probe (data not shown).
All 8 patients received HAART and experienced a progressive improvement of skin symptoms (Figure 3 ), leading to complete remission in 5 case patients and to partial remission in the 3 Figure 1 . Histological sections of lesional skin. Panels A (original magnification, ϫ40) and B (original magnification, ϫ200) show skin sections from patient 6 stained with hematoxylin and eosin, demonstrating a dense dermal infiltration by a majority of small lymphocytes, with prominent epidermotropism, in a mycosis fungoides-like pattern. Immunostaining with anti-CD3 (C ) and anti-CD8 (D ) monoclonal antibodies show that virtually all lymphocytes belong to the CD8 T cell lineage. Most skin lymphocytes express a CD45RO + memory phenotype (E ), whereas only a few express granzyme B (F ) or T cell-restricted intracellular antigen (G ). others (Table 3 ). Histopathological analysis of sequential skin biopsies in patient 2 showed a dramatic regression of the infiltrate at the time of clinical response. The time to reach maximal clinical response following HAART onset was available for 7 patients and ranged from 3 to 8 months (mean, 5.3 months) ( Table 3) . It is worth outlining that remission of skin symptoms was obtained without adjuvant therapy in all but 2 case patients (patient 2 and patient 8). Patient 2 was treated with CHOP systemic antineoplastic polychemotherapy before receiving HAART, but the former led to clear deterioration with progression of skin lesions. The onset of HAART led to dramatic regression of skin symptoms, although photosensitivity persisted ( Figure 3 ). Patient 8 initially received HAART with a partial improvement of skin symptoms after 3 weeks of treatment. A few weeks later, he received CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) because of suspicion of non-Hodgkin lymphoma. Treatment has consisted of 3 courses of chemotherapy. HAART therapy and/or CHOP chemotherapy led to complete remission.
The plasma HIV load rapidly decreased during HAART and returned to undetectable levels at the time maximal clinical response was reached in all but 2 cases (Table 2 ). In these 2 patients, the HIV load dramatically decreased from 6.3 to 2.3 log 10 copies/mL and from 7 to 3.3 log 10 copies/mL, respectively. The clinical efficacy of antiretroviral combined drug therapy also paralleled the increase of CD4 + blood cell count, with a median value increasing from 23 cells/mm 3 before onset of HAART to 145 cells/mm 3 when maximal clinical response was obtained (Table 2) . Peripheral blood eosinophil counts also returned to normal levels at the time of clinical response (median count, 220 cells/mm 3 ; range, 120-300 cells/mm 3 ). The parallel course of skin symptoms and of immunological and virological variables was striking in patient 4, who entered into complete remission 3 months after the onset of treatment with a combination of lopinavir/ritonavir and didanosine/zidovudine, concomitant with an undetectable HIV plasma load and with reconstitution of CD4 + peripheral pool. He stopped HAART and presented with a relapse of skin symptoms leading to severe erythroderma and diffuse lymphadenopathy 3 months after HAART withdrawal. At the time of relapse, a profound CD4 lymphocytopenia (6 cells/mm 3 ) and increased plasma HIV load (5 log 10 copies/mL) were observed. The restart of HAART, including lamivudine, ritonavir, atazanavir, and stavudine, was rapidly followed by a dramatic remission again, with undetectable plasma HIV load and an increase of blood CD4 count up to 53 cells/mm 3 .
DISCUSSION
In the present work, we analyzed 8 HIV-1-infected patients presenting with a severe CD8 + cytotoxic T cell skin infiltrative disease. The clinical findings observed in these patients are in accordance with those identified in other reports [11] [12] [13] [14] [15] [16] [17] . Most patients exhibited a profound immune deficiency at the time of skin symptoms, as outlined by a severe CD4 lymphocytopenia. Although dermatological findings were suggestive of CTCL (ie, pruriginous erythematous infiltrated plaques associated with palmoplantar keratoderma and lymphadenopathy), other features were distinctive, such as marked pigmentation of skin lesions or worsening effect of ultraviolet irradiation on skin symptoms.
The histopathological presentation consisting of a superficial and sometimes middermal CD8 + -predominant lymphocytic infiltrate was homogeneous among the patients. However, the density and the overall pattern of the infiltrate (interface dermatitis, CTCL-like, or dermatitis-like) may vary greatly from one patient to another, as well as in consecutive biopsies in the same patient. In contrast to CTCL occurring in HIV-negative patients who are predominantly expressing CD4 [20] , all reported case of HIV-related CTCL-like cutaneous infiltration, including those in this work, demonstrate a predominant CD8 cytotoxic phenotype [12, 15] . Although CTCL is often associated with a loss of expression of some differentiation antigens of mature T cells, such as CD2, CD5, and CD7 [21] , the results of other studies did not show any immunophenotypic aberration in HIV-related CD8 + CTCL-like cutaneous infiltrations. Furthermore, infiltrative CD8 + T cells showed a weak but re- producible expression of the molecules T cell-restricted intracellular antigen and granzyme B, indicating their belonging to the cytotoxic lineage. On the other hand, this low expression of cytotoxicity molecules is in accordance with other studies demonstrating their impaired expression at local sites of HIV replication [22] . Alternatively, the infiltrate might include CD8 + cells with noncytotoxic anti-HIV response, as defined by Mackewicz et al [23] . Moreover, we were unable to detect a predominant TCR clonal rearrangement in the skin biopsy and in the peripheral blood mononuclear cells of all patients included in this study. The polyclonal pattern of the CD8 infiltrate is discrepant with the monoclonal one of TCR genes which has been detected in CTCL [24, 25] and in a CD8 cutaneous lymphoproliferation occurring in a patient coinfected with HIV-1 and human Tlymphotropic virus II [9] .
Finally, in our patients, the activated CD8 + cytotoxic T phenotype of infiltrating lymphocytes and their polyclonal status clearly differ from the aberrant phenotypes and the frequent monoclonal pattern of lymphocytic expansions reported in HIV-seronegative patients and support the HIV-driven, reactional nature of the disease, which belongs to the spectrum of diseases related to a tissular infiltration by CD8 + cytotoxic T cells occurring during the course of HIV infection. This latter entity also includes infiltrative disorders involving the spleen [26] , the lungs [27] , and the salivary glands [28] . This hypothesis is supported by functional studies; CD8 + T cells derived from lesional skin of HIV-infected patients with CD8 infiltrative disease, including patient 1 and 2, revealed both their cytotoxic T cell lineage and their specificity toward HIV antigens [13, 18] .
The present observation that remission of skin symptoms during HAART paralleled both the reduction of HIV plasma RNA load and the immune reconstitution of peripheral blood CD4 + lymphocytes pool provides support for a causal relationship between HIV-induced immune deficiency and the CD8 expansion. This apparent paradigm may be explained in part by a defect of the CD4 + regulatory T cell pool, leading to an uncontrolled cytotoxic T lymphocyte activation [29] . On the other hand, the early increase in circulating CD8 count following the onset of HAART might result from the recirculation of CD8 lymphocytes from lesional skin to the peripheral blood compartment. The mechanisms leading to the predominant skin localization of cytotoxic T lymphocyte infiltration in this syndrome remains to be deciphered. Further physiopathological studies are warranted to address the hypothesis that HIVspecific cytotoxic T lymphocytes would cross-react with skinderived self antigens.
In conclusion, this study provides strong support for the reactive, nonmalignant nature of HIV-related CD8 + T cell skin infiltrative disease, a diagnosis which should be raised in HIVinfected patients with chronic inflammatory skin eruption and lymphadenopathy. It also emphasizes the control of HIV replication and the correction of its resulting immune dysregu-lation by HAART as the optimal therapeutic strategy. On the other hand, even though cytotoxic chemotherapy might have been helpful in one of our cases, we would not recommend using it as first line therapy, because efficient HAART is rapidly leading to striking remission of skin symptoms.
